跳转至内容
Merck
所有图片(2)

文件

PZ0012

Sigma-Aldrich

Sunitinib malate

≥98% (HPLC), powder, receptor tyrosine kinase inhibitor

别名:

N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic acid (1:1) salt, SU 011248, SU 11248, SU112248

登录查看公司和协议定价
所有图片(2)

About This Item

经验公式（希尔记法）:
C22H27FN4O2 · C4H6O5
CAS号:
341031-54-7
分子量:
532.56
MDL號碼:
MFCD08282795
分類程式碼代碼:
12352200
PubChem物質ID:
329823681
NACRES:
NA.77

product name

Sunitinib malate, ≥98% (HPLC)

化驗

≥98% (HPLC)

形狀

powder

溶解度

DMSO: >10 mg/mL

儲存溫度

room temp

SMILES 字串

O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C

InChI

1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1

InChI 密鑰

LBWFXVZLPYTWQI-IPOVEDGCSA-N

基因資訊

human ... CSF1R(1436) , FLT1(2321) , FLT3(2322) , FLT4(2324) , KDR(3791) , KIT(3815) , PDGFRA(5156) , PDGFRB(5159) , RET(5979)

正在寻找类似产品? 访问 产品对比指南

應用

Sunitinib malate has been used:
  • to study its mechanism in the inhibition of MCF-7 cell migration and angiogenesis
  • as a reference molecule to compare its docking energies with other ligands/vascular endothelial growth factor receptor (VEGF) receptor blocker
  • used in proliferation assay

生化／生理作用

Sunitinib has greater bioavailability and potency compared to other inhibitors. It prevents angiogenesis.
Sunitinib malate is a receptor tyrosine kinase inhibitor, which targets VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, FLT3, CSF-1R, and RET. Sunitinib malate is an anticancer drug.

特點和優勢

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H360,H372

危險分類

Repr. 1B - STOT RE 1 Oral

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 2

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Iris Uribesalgo et al.
EMBO molecular medicine, 11(8), e9266-e9266 (2019-07-04)
Angiogenesis is a hallmark of cancer, promoting growth and metastasis. Anti-angiogenic treatment has limited efficacy due to therapy-induced blood vessel alterations, often followed by local hypoxia, tumor adaptation, progression, and metastasis. It is therefore paramount to overcome therapy-induced resistance. We
Sunitinib: from rational design to clinical efficacy
Chow LQM and Eckhardt SG
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(7), 884-896 (2007)
Nils Ohnesorge et al.
Frontiers in pharmacology, 10, 508-508 (2019-06-11)
Unbiased screening of large randomized chemical libraries in vivo is a powerful tool to find new drugs and targets. However, forward chemical screens in zebrafish can be time consuming and usually >99% of test compounds have no significant effect on
Suma Choorapoikayil et al.
Disease models & mechanisms, 6(5), 1159-1166 (2013-05-31)
Angiogenesis, the emergence of vessels from an existing vascular network, is pathologically associated with tumor progression and is of great interest for therapeutic intervention. PTEN is a frequently mutated tumor suppressor and has been linked to the progression of many
In-silico screening and In-vitro validation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) inhibitors
Saraswat D, et al.
Bioinformation, 10(5), 273-273 (2014)
查看所有相关文献

商品

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门